Insulet (NASDAQ:PODD) Stock Rating Upgraded by Barclays

Insulet (NASDAQ:PODD) was upgraded by stock analysts at Barclays to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks reports.

PODD has been the subject of several other reports. JPMorgan Chase & Co. reissued a “neutral” rating and set a $152.00 target price (down from $275.00) on shares of Insulet in a research note on Thursday, August 6th. Wall Street Zen lowered Insulet from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 9th. BTIG Research cut Insulet from a “buy” rating to a “neutral” rating in a research note on Thursday, August 6th. Weiss Ratings reissued a “sell (d+)” rating on shares of Insulet in a research report on Monday, September 21st. Finally, Royal Bank Of Canada cut their target price on shares of Insulet from $245.00 to $160.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Thirteen research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Insulet currently has a consensus rating of “Hold” and an average price target of $193.48.

Insulet Price Performance

Shares of PODD opened at $134.47 on Wednesday. Insulet has a fifty-two week low of $126.40 and a fifty-two week high of $354.88. The firm’s 50 day moving average price is $142.33 and its 200 day moving average price is $159.81. The company has a market cap of $9.33 billion, a P/E ratio of 25.13, a PEG ratio of 1.06 and a beta of 1.11. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating the consensus estimate of $1.47 by $0.19. The company had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm’s revenue was up 23.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, research analysts forecast that Insulet will post 6.51 earnings per share for the current fiscal year.

Institutional Trading of Insulet

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in shares of Insulet during the 2nd quarter worth about $1,018,582,000. Arrowstreet Capital Limited Partnership increased its holdings in shares of Insulet by 462.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after acquiring an additional 1,011,369 shares during the last quarter. Man Group plc acquired a new stake in shares of Insulet during the 2nd quarter worth about $78,746,000. Amundi raised its position in shares of Insulet by 13.6% during the 2nd quarter. Amundi now owns 507,847 shares of the medical instruments supplier’s stock worth $77,320,000 after acquiring an additional 60,929 shares in the last quarter. Finally, Bank of America Corp DE purchased a new stake in Insulet during the second quarter worth approximately $64,921,000.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps.

Insulet’s product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system.